Changes in the Clinical Characteristics of Kawasaki Disease After Coronavirus Disease (COVID-19) Pandemic: A Database Analysis

Beom Joon Kim, Arum Choi, Hwan Soo Kim, Jin-Hee Oh, Jae-Young Lee, Sukil Kim, Ji-Whan Han, Kyunghoon Kim, and Hyun Hee Kim

1Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea
2Department of Preventive Medicine and Public Health, College of Medicine, The Catholic University of Korea, Seoul, Korea
3Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Korea
4Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea

ABSTRACT

Background: The impact of the coronavirus disease 2019 (COVID-19) pandemic on Kawasaki disease (KD) has not yet been established. We investigated changes in the observed number and severity of KD cases and accompanying coronary artery complications during the COVID-19 pandemic in Korea.

Methods: This retrospective observational study included patients aged < 18 years with acute-phase KD diagnosed between March 2018 and February 2021. Data were extracted from the Clinical Data Warehouse that houses data from five affiliated university hospitals in Korea. We analyzed changes in the number of patient admissions and clinical characteristics, including cardiac complications, before and after the onset of the COVID-19 pandemic.

Results: A total of 475 admissions were included in the analysis. After March 2020, we observed a significant decrease of 33% in the number of hospitalizations for KD compared with the average number of hospitalizations during the previous 2 years. The number of admissions per month significantly decreased by 7.9 persons/month (95% confidence interval, −13.8 to −2.0; P < 0.05) compared with that before COVID-19. By contrast, the proportion of patients aged < 1 year with KD increased. The proportion of patients with refractory KD and the rate of cardiac complications did not change significantly.

Conclusion: Since the onset of the COVID-19 pandemic, the total number of hospital admissions for KD has decreased in Korea. Although the proportion of admissions of infants aged < 1 year increased, no changes were observed in clinical courses and complications.

Keywords: Kawasaki Disease; Coronavirus Disease 2019; Complications; Children

INTRODUCTION

Kawasaki disease (KD), an idiopathic systemic febrile vasculitis, predominantly affects children aged < 5 years. It is the most common cause of pediatric acquired heart disease in developed countries.1 A high KD incidence has been reported in Northeast Asian countries,
and Korea has the second highest incidence after Japan. According to 2015–2017 nationwide surveys on KD in Korea, the KD incidence has been steadily increasing since 2000. The etiology of KD remains unknown, but the leading theory is that preceding infection triggers immune system activation in a susceptible child. The seasonality of KD incidence supports this hypothesis.

The coronavirus disease 2019 (COVID-19) was declared a pandemic on March 11, 2020. In Korea, the first case was announced on January 20, 2020, and as of August 15, 2021, there were 223,920 confirmed cases and 2,156 COVID-19-related deaths. After the first case, people voluntarily wore masks and refrained from going out. As the number of confirmed cases increased, the Korean government gradually raised the infectious disease risk alert level and officially implemented enhanced social distancing on March 20, 2020. Accordingly, interventions such as the mandatory wearing of masks in public places, restrictions on private gatherings and on the use of public and multipurpose facilities, and school closures were implemented.

Social distancing has led to an overall reduction in pediatric cases and a dramatic decrease in the incidence of pediatric respiratory tract infections worldwide. In Finland, after a national lockdown in early 2020, pediatric emergency room visits for respiratory infections decreased by a third; further, the nationwide number of pediatric influenza and respiratory syncytial viral infection cases decreased. Similarly, not only in Korea but also in Canada and Taiwan, hospital visits for pediatric respiratory symptoms decreased by > 50%.

Against this background, it is meaningful to investigate changes in the incidence of KD in Northeast Asia since the COVID-19 outbreak. We aimed to confirm the change in the number of patients with KD during the COVID-19 pandemic by examining the seasonality of KD through a sufficiently long observation period and identifying changes in clinical characteristics and prognosis of KD using electronic medical record data.

**METHODS**

**Study design and population**

All data were extracted from the Clinical Data Warehouse (CDW), which provides access to a large database of patients from five hospitals in Korea: Seoul St. Mary’s Hospital, Yeouido St. Mary’s Hospital, Bucheon St. Mary’s Hospital, Uijeongbu St. Mary’s Hospital, and St. Vincent Hospital.

We extracted the data of patients with KD who were aged < 18 years from the CDW using the International Classification of Diseases, 10th Revision (ICD-10), code for KD (M30.3) between March 2018 and February 2021. We included patients who were in the acute phase of KD and excluded those with a secondary diagnosis and those who did not receive acute-phase treatment. Data analysis was performed after excluding readmission and duplicate data.

The acute phase of KD was defined as a primary diagnosis of KD treated with intravenous immunoglobulin (IVIG) therapy or a moderate (30–50 mg/kg/day) to high (80–100 mg/kg/day) dose of aspirin as anti-inflammatory therapy. A primary diagnosis of KD was defined as the first diagnosis of KD with the ICD-10 code M30.3. Each hospitalization for acute-phase KD was considered as an independent case. However, readmission within 60 days of the
initial episode was considered as a continuation of the acute phase and was excluded. In addition, we identified duplicate data by reviewing the medical records of patients of the same sex and with the same birthdate.

**Outcome definitions and measurements**

We assessed the number of hospitalizations per month for 3 consecutive years during the study period. We divided hospitalizations into two groups based on whether they occurred before or after March 2020, that is, before and after the onset of the COVID-19 pandemic, to determine its effect on KD.

We also compared changes in the proportion of patients with refractory KD before and after the onset of the COVID-19 pandemic as well as differences in the disease's clinical characteristics. Refractory KD was defined as resistance to the first IVIG infusion requiring the following additional treatments after at least 2 calendar days: additional IVIG, corticosteroids, and infliximab.

The following cardiac complications were investigated using echocardiographic data captured within 2 months of the diagnosis of KD: coronary artery abnormalities, valvular regurgitation, pericardial effusion, and ventricular form and function. If echocardiography was performed multiple times within the 2 months, for each observed complication, the dataset depicting the highest severity of findings was selected for analysis. Coronary artery abnormalities were defined as Z-scores for one or more branches meeting the criteria, based on the Z-score classification system recommended in the American Heart Association guidelines updated in 2017. Valvular regurgitation was defined as mild to more severe degrees of regurgitation in the tricuspid and aortic valves. Ventricular form and function were evaluated using left ventricle end-diastolic and end-systolic diameters and ejection fraction as indicators.

**Statistical analysis**

We performed a segmented regression analysis, a statistical method for estimating the impact of events in time series data, to identify changes in the monthly number of acute-phase KD. This method examines the changes in the level and trend of the measure following an event. The event in this study was the COVID-19 pandemic in Korea, the independent variable was the week of the year, and the dependent variable was the number of admissions for KD. As seasonal variations existed in the trend of the changes in the number of KD, the data were adjusted for seasonality.

To compare the characteristics of the two groups divided into the pre- and post-pandemic periods, we used Pearson's $\chi^2$ test with Yates' continuity correction or Fisher's exact test for qualitative variables. In particular, only Pearson's $\chi^2$ test was used for the comparison of the age distribution of the three groups. Moreover, Student's $t$-test or the Mann–Whitney $U$ test was used for quantitative variables.

All analyses were performed using R version 4.0.0 (R Foundation for Statistical Computing, Vienna, Austria), with the probability level for significance set at a $P$ value of <0.05.

**Ethics statement**

This study was approved by the Institutional Review Board (IRB) of the Catholic University of Korea and the requirement for informed consent was waived (IRB approval No. XC21WADI0049).
RESULTS

Demographic data and clinical characteristics of patients with KD after COVID-19

Data from 1,219 hospital admissions with the ICD-10 code M30.3 were extracted between March 1, 2018 and February 28, 2021. Among these, 478 patients with acute-phase KD were identified, and 701 patients with a secondary diagnosis of KD and 40 patients who did not receive treatment with either IVIG or aspirin (anti-inflammatory dose) were excluded. In addition, three patients who were readmitted within 60 days of the initial episode were excluded. Finally, 475 patients were included in the analysis (Fig. 1). There were no duplicate admissions resulting from transfers between the five hospitals among patients with the same birthdate and of the same sex.

The demographic data and clinical characteristics are summarized in Table 1. Children diagnosed with acute-phase KD after the COVID-19 outbreak were younger than those diagnosed with KD before the outbreak, and there was no difference based on sex. Further, there were no differences in the Sano score, a predictive system for IVIG resistance, between the two groups. Laboratory tests revealed no significant differences in variables apart from the C-reactive protein (CRP) level and neutrophil fractions. The CRP level and neutrophil fractions were lower after the pandemic onset than during the pre-pandemic period. Most of the children in both groups received IVIG as the first treatment, but five patients received only an anti-inflammatory dose of aspirin. After the COVID-19 outbreak, the average duration of hospitalization was shorter. No patients in our sample tested positive for COVID-19 since the onset of the pandemic.

Decrease in the number of patients with KD after COVID-19

We identified 406 cases between March 2018 and February 2020 and 69 cases between March 2020 and February 2021. Since March 2020, the number of KD cases has decreased by 33.9% compared with the average number in the previous 2 years. Segmented regression analysis was used to determine the effect of COVID-19 on the number of KD cases per month; a significant decrease was found in the number of KD cases in March 2020, between the time when COVID-19 was first reported in Korea and the time when the government implemented
an enhanced social distancing policy. In March 2020, there was a significant decrease of 7.9 persons/month (95% confidence interval [CI], −13.8 to −2.0; \( P = 0.009 \)). Prior to this timepoint, the number of admissions was decreasing at a rate of 0.1 persons/month (95% CI, −0.3 to 0.1; \( P = 0.366 \)); after this timepoint, the number of KD cases started decreasing at a rate of 0.2 persons/month (95% CI, −0.9 to 0.5; \( P = 0.572 \)). However, these differences were not statistically significant (Fig. 2).

Proportion of patients with refractory KD after COVID-19
The demographic data and clinical characteristics of patients with refractory KD are summarized in Table 2. We identified 80 cases of refractory KD between March 2018 and February 2020 and 19 cases between March 2020 and February 2021. The proportion of patients with refractory KD did not change significantly since the COVID-19 outbreak (19.7% vs. 27.5%, \( P = 0.187 \)). In both groups, the predominantly administered second treatment was a second dose of IVIG (63.8% vs. 68.4%, \( P = 0.908 \)), followed by intravenous steroid treatment (55% vs. 57.9%, \( P = 1.000 \)). No patient in either group received a third dose of IVIG.

KD-related cardiac complications after COVID-19
Among the patients with KD diagnosed after the COVID-19 outbreak, 57 underwent echocardiography within 2 months of admission. Of these patients, seven (12.8%) exhibited coronary complications, and five (8.8%) exhibited pericardial effusion. Valvular regurgitation and ventricular dysfunction or dilatation were not observed. There were no statistically significant differences before and after the COVID-19 outbreak (Table 3).

### Table 1. Characteristics of patients with KD before and after the COVID-19 pandemic

| Variables | Mar 2018–Feb 2020 (n = 406) | Mar 2020–Feb 2021 (n = 69) | \( P \) value |
|-----------|-----------------------------|-----------------------------|---------------|
| Age at onset, yr | | | |
| < 1 | 75 (18.5) | 22 (31.9) | 0.012 |
| 1–5 | 262 (64.5) | 42 (60.9) | |
| ≥ 5 | 69 (17) | 5 (7.2) | |
| Male | 224 (55.2) | 38 (55.1) | 1.000 |
| Weight, kg | | | < 0.01 |
| Sano score ≥ 2 points\(^a\) | 39 (9.8) | 4 (6) | 0.440 |
| Hypotension\(^b\) | 8 (2.0) | 0 | |
| Laboratory values at admission | | | |
| Leukocytes, \( \times 10^9 /L \) | 11.29 (8.51–14.79) | 10.66 (7.56–14.08) | 0.267 |
| Neutrophils, % | 58.7 (41.6–71.5) | 50.4 (31.0–66.1) | 0.012 |
| Platelets, \( \times 10^9 /L \) | 347 (291–417) | 368 (300–441) | 0.157 |
| ESR, mm/h | 49 (37–74) | 48 (29–62) | 0.104 |
| CRP, mg/dL | 5.77 (2.96–9.38) | 4.41 (2.12–8.41) | 0.016 |
| Sodium, mEq/L | 138 (136–139) | 137 (135–139) | 0.235 |
| ALT, U/L | 32 (15–92) | 35 (16–96) | 0.575 |
| Albumin, g/dL | 3.5 (3.2–3.9) | 3.4 (3.1–3.8) | 0.421 |
| First line treatment | | | |
| IVIG | 402 (99) | 68 (98.6) | 1.000 |
| Aspirin (anti-inflammatory) | 398 (98) | 63 (91.3) | < 0.01 |
| Refractory KD | 80 (19.7) | 19 (27.5) | 0.187 |
| Duration of hospitalization (day) | 7 (6–9) | 6 (5–9) | 0.041 |

Variables are expressed as number (%) or median (interquartile range). KD = Kawasaki disease, COVID-19 = coronavirus disease 2019, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein, ALT = alanine transaminase, IVIG = intravenous immunoglobulin.

\(^a\)Sano score: scores calculated through the Sano predictive system as follows: 1) AST level ≥ 200 IU/L, 1 point; 2) CRP level ≥ 7 mg/dL, 1 point; and 3) total bilirubin level ≥ 0.9 mg/dL, 1 point.

\(^b\)Hypotension is defined as a systolic blood pressure that is less than the fifth percentile of the normal blood pressure for the patient’s age.
Fig. 2. Segmented regression analysis of the number of patients with KD. Compared with that in Mar 2018–Feb 2020 (A), the number of patients with KD per month in Mar 2020–Feb 2021 (B) has significantly decreased by 7.9 persons/month (95% CI, −13.8 to −2.0; P < 0.05). During the periods of 2018–2020 (A) and 2020–2021 (B), there was a decreasing trend in the number of admissions, but this trend was not statistically significant.

KD = Kawasaki disease, CI = confidence interval, COVID-19 = coronavirus disease 2019.

Table 2. Characteristics of patients with refractory KD before and after the COVID-19 pandemic

| Variables                        | Mar 2018–Feb 2020 (n = 80) | Mar 2020–Feb 2021 (n = 19) | P value |
|----------------------------------|----------------------------|-----------------------------|---------|
| Age at onset, yr                 |                            |                             | 0.712   |
| < 1                              | 13 (16.25)                 | 4 (21.1)                    |         |
| 1–5                              | 53 (66.25)                 | 13 (68.4)                   |         |
| ≥ 5                              | 14 (17.5)                  | 2 (10.5)                    |         |
| Male                             |                            |                             | 0.744   |
|                                 | 48 (60)                    | 10 (52.6)                   |         |
| Weight, kg                       | 14.7 (10.7–17.2)           | 13.1 (10.1–16.3)            | 0.346   |
| Sano score ≥ 2 pointsa           | 19 (23.8)                  | 2 (11.1)                    | 0.388   |
| Hypotensionb                     |                            |                             |         |
|                                 | 0                          | 0                            |         |
| Laboratory values at admission   |                            |                             |         |
| Leukocytes, ×10^9/L              | 11.10 (8.66–14.13)         | 12.98 (11.31–16.96)         | 0.064   |
| Neutrophils, %                   | 66.4 (53.7–78.7)           | 67.1 (59.6–78.3)            | 0.646   |
| Platelets, ×10^9/L               | 337 (263–404)              | 304 (255–392)               | 0.680   |
| ESR, mm/h                        | 45 (38–63)                 | 39 (21–60)                  | 0.122   |
| CRP, mg/dL                       | 7.81 (4.28–12.43)          | 8.64 (4.68–11.71)           | 0.887   |
| Sodium, mEq/L                    | 137 ± 3                    | 137 ± 2                     | 0.714   |
| ALT, U/L                         | 67 (20–171)                | 66 (24–158)                 | 0.945   |
| Albumin, g/dL                    | 3.2 (3.0–3.6)              | 3.4 (3.0–3.8)               | 0.465   |
| First line treatment             |                            |                             |         |
| IVIG                             | 80 (100)                   | 19 (100)                    | 1.000   |
| Aspirin (anti-inflammatory)      | 76 (95.0)                  | 17 (89.5)                   | 0.709   |
| Second line treatment            |                            |                             |         |
| 2nd IVIG                         | 51 (63.8)                  | 13 (68.4)                   | 0.908   |
| 3rd IVIG                         | 0                          | 0                            |         |
| IV corticosteroid                | 44 (55)                    | 11 (57.9)                   | 1.000   |
| Oral corticosteroid              | 35 (43.8)                  | 10 (52.6)                   | 0.658   |
| Infliximab                       | 1 (2.3)                    | 0                            |         |
| Duration of hospitalization, day | 6 (4–9)                    | 5 (4–7)                     | 0.516   |

Variables are expressed as number (%), mean ± standard deviation, or median (interquartile range).

KD = Kawasaki disease, COVID-19 = coronavirus disease 2019, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein, ALT = alanine transaminase, IVIG = intravenous immunoglobulin, IV = intravenous.

aScores calculated through the Sano predictive system as follows: 1) AST level ≥ 200 IU/L, 1 point; 2) CRP level ≥ 7 mg/dL, 1 point; and 3) total bilirubin level ≥ 0.9 mg/dL, 1 point.

bHypotension is defined as a systolic blood pressure that is less than the fifth percentile of the normal blood pressure for the patient’s age.
DISCUSSION

Our data demonstrate that the monthly number of KD cases has significantly decreased since the outbreak of the COVID-19 pandemic. By contrast, the proportion of patients aged < 1 year with KD has increased compared with that before the outbreak. However, the proportion of patients with refractory KD did not change. Moreover, no significant changes were observed in the rates of coronary complications and pericardial effusion.

To the best of our knowledge, this is the first study to examine the changes in the clinical features and complications of KD in Korea after the COVID-19 outbreak. In addition, as this was a multicenter study conducted over a period of > 1 year after the onset of the COVID-19 pandemic, we were able to fully consider the seasonal variability in the occurrence of KD.

There have been a few reports regarding a decrease in the number of KD after the COVID-19 outbreak. A nationwide observational study in Korea reported that the number of patients with KD decreased by 40% from February to September 2020 compared to the same period in the year before COVID-19. On the other hand, no changes were observed in the proportion of patients with refractory KD compared to that reported in 2019. These results are consistent with our study. However, the observation period in the earlier nationwide study was insufficient for confirming the incidence of KD, which peaks in winter. Additionally, since it represents a big data study based on records derived from the National Health Insurance Service database, there may have been errors in the estimation of the incidence of KD as a result of duplicate or heterogeneous data. Moreover, this earlier study did not exclude Kawasaki-like diseases, such as adenovirus infection and measles. Our study, on the other hand, included all seasons as we examined data over a 1-year period since the onset of the COVID-19 pandemic. In addition, we used a detailed operational definition of KD and an electronic medical record review to exclude Kawasaki-like diseases and duplicate cases to the greatest possible extent.

In Japan, three studies reported a decrease in the number of patients with KD after the COVID-19 outbreak. Of these, two multicenter studies reported reductions of 47.1% and 53%, respectively, and one nationwide study reported a reduction of 35%. These studies compared data from 2020 to records from the last 3–5 years. However, they were all focused on the correlation between KD and infectious diseases, and lack a discussion of changes in the clinical features of KD. One multicenter study reported that the prominent clinical features of patients with KD in 2020 were a significantly lower white blood cell count, neutrophil count, and refractory KD ratio and that there was no significant difference in cardiac complications. However, this study was based on the data of only 36 patients collected from April to May, which represents a short study period as well as a small number of participants. Here, we investigated changes in the clinical features of both KD and

Table 3. Cardiac complications of KD before and after the COVID-19 pandemic

| Variable                | Pre-pandemic period (n = 321) | Post-pandemic period (n = 57) | P value |
|-------------------------|-------------------------------|-------------------------------|---------|
| Cardiac complication    |                               |                               | 0.133   |
| Coronary artery complication | 21 (6.5)                   | 7 (12.3)                     |         |
| Pericardial effusion    | 13 (4.1)                     | 5 (8.8)                      |         |
| Valvular regurgitation  | 8 (2.5)                      | 0 (0)                        |         |
| Left ventricle dilatation | 1 (0.3)                    | 0 (0)                        |         |

Data are expressed as number (%).
KD = Kawasaki disease, COVID-19 = coronavirus disease 2019.
refractory KD before and after the onset of the COVID-19 pandemic, and we reviewed the results of serial echocardiography examinations conducted over 2-month periods in these patients during the entire study period to determine whether cardiac complications occurred.

The exact cause of the decrease in the number of KD remains unclear. However, considering the dominant hypothesis that a preceding infection acts as a trigger for inflammation leading to KD, the main reason could be the decrease in pediatric infective diseases due to social distancing. Similar hypotheses have been proposed in previous studies. After the first case of COVID-19 in Korea, a high number of people started wearing masks and refrained from going out even before the government officially declared that social distancing was necessary, which led to a nationwide decrease in respiratory infections. In addition, at our institution, there was an immediate decrease in emergency room visits for pediatric infectious diseases after the first case of COVID-19. With regard to KD, a significant decrease was observed from March, later than the one observed for infective diseases. These findings support the notion that social distancing is associated with the decrease in pediatric infectious diseases and corroborate the antecedent infection theory of KD.

Another explanation for the decrease in the number of admitted patients with KD may be the reluctance of caregivers to visit a hospital for fear of exposure to COVID-19. A multinational study found that 20% of caregivers said that they were reluctant to visit the emergency room for fear of being infected with COVID-19 at the hospital. In Italy, there have been several reports of aggravation of disease caused by delays in visits to pediatric emergency facilities due to caregivers’ reluctance. However, some previous studies have suggested that the reluctance of caregivers and patients to visit a hospital for fear of exposure to the virus was not associated with the reduced incidence of KD. One of these studies inferred that caregivers would not delay visits to the hospital due to the serious clinical presentation of KD; another study suggested that there was no difference in the duration of fever (in days) at the time of admission. In our sample, the length of hospital stay of patients with KD was significantly shortened after COVID-19, but this was not true for refractory KD. This may be due to fewer patients visiting the hospital very early in the clinical course of KD or due to patients being discharged earlier, which is not the case in refractory KD. Therefore, our findings may indeed be evidence of the fear of caregivers of contracting COVID-19 at a hospital. However, we are somewhat limited in the interpretation of our data, because we did not collect data on clinical day of KD on admission or on incomplete KD.

The proportion of children aged < 1 year with KD was larger after than before COVID-19 in our sample. Age < 1 year is one of the known risk factors for refractory KD. A previous study has suggested that children aged < 1 year have a higher risk of contracting respiratory infections through parents or others because wearing a mask is not recommended in this age group. For this reason, the decrease in the number of patients with KD during the COVID-19 pandemic may be less pronounced in these children than in other age groups. However, our study was not designed to investigate this question, since it is only one of several factors we assessed, and further research is therefore needed.

Our results demonstrate no difference in the proportion of patients with refractory KD, pericardial effusion, and coronary artery complications between the two assessed time periods. It is well known that refractory KD is associated with prolonged fever and more severe coronary outcomes. In addition, pericardial effusion is observed in 6–24% of
patients with acute-phase KD, which is suggestive of severe cardiac inflammation and is has been reported to be strongly associated with coronary artery complications.31 Therefore, our results indicate that there was no change in the severity of KD before and after COVID-19.

After the onset of the COVID-19 pandemic, there has been an increase in the incidence of multisystem inflammatory syndrome in children (MIS-C), a condition with clinical features similar to those of KD, in North America and Europe, which has been causing concern worldwide.32,33 However, patients with MIS-C are generally older and have gastrointestinal symptoms, hemodynamic instability, and lower platelet counts, which are different from the features of classic KD.34 Additionally, very few MIS-C cases have been reported in Korea and Japan, where the prevalence of KD is high.35-38 In our study, all patients with KD who presented during the COVID-19 pandemic underwent screening for COVID-19 using polymerase chain reaction (PCR) tests prior to hospitalization. All PCR tests were negative, however, and there were thus no confirmed cases of COVID-19 in our sample. We assume that this is due to the overall smaller number of confirmed cases of COVID-19 in Korea compared to North America and Europe as well as to differences in susceptibility based on race.

This study has several limitations. First, this was a retrospective study on data that were extracted from the CDW, which provides access to a large database of patients from five hospitals. Second, since the ICD-10 coding system was used, there may be inaccuracies in the diagnostic data. These are, however, inherent limitations of studies using data from administrative databases. Moreover, we attempted to increase the accuracy of our results by using more detailed operational definitions and verification procedures to avoid including duplicate cases. Third, the diagnosis and treatment of KD did not follow the same protocol but was at the discretion of individual physicians at the five included hospitals, which resulted in differences in aspirin treatment and the non-implementation of echocardiography in all cases.

The strength of our study is that we identified changes in clinical features and complications in addition to changes in the number of patients with KD admitted to hospitals. For this purpose, we used data from a large database of five hospitals that provides a variety of clinical data from de-identified patients, such as medical records, drug prescription histories, laboratory test results, and imaging findings. In addition, since the five hospitals are all located in the Seoul Metropolitan Area where half of the Korean population resides, potential regional deviations could be reduced in our study. The trend of the number of patients with KD admitted to the hospital during the 2 years before the COVID-19 pandemic at these five hospitals was not significantly different from that shown by the National Health Insurance Service data during this same period. Therefore, we consider our findings reliable.

In conclusion, this study reveals a decrease in the number of patients with KD after the onset of the COVID-19 pandemic. We also found that the proportion of children aged < 1 year with KD was larger after the onset of the pandemic than during the pre-pandemic period. Although no change in disease severity was observed in our sample, our findings need to be interpreted with caution because age < 1 year is a risk factor for refractory KD. Further long-term studies are needed to identify whether the decreased incidence of KD persists.
REFERENCES

1. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. *Circulation* 2017;135(17):e927-99.

2. Singh S, Vignesh P, Burgner D. The epidemiology of Kawasaki disease: a global update. *Arch Dis Child* 2015;100(11):1084-8.

3. Kim GB, Eun LY, Han JW, Kim SH, Yoon KL, Han MY, et al. Epidemiology of Kawasaki disease in South Korea: a nationwide survey 2015-2017. *Pediatr Infect Dis J* 2020;39(11):1012-6.

4. Rife E, Gedalia A. Kawasaki disease: an update. *Curr Rheumatol Rep* 2020;22(10):75.

5. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. *Acta Biomed* 2020;91(1):157-60.

6. Ministry of Health and Welfare. Coronavirus disease-19, Republic of Korea. http://ncov.mohw.go.kr/en. Updated 2021. Accessed August 1, 2021.

7. Park IN, Yum HK. Stepwise strategy of social distancing in Korea. *J Korean Med Sci* 2020;35(28):e264.

8. Ministry of Health and Welfare. All about Korea’s response to COVID-19. https://www.mofa.go.kr/eng/brd/m_22742/view.do?seq=3&srchFr=&srchTo=&srchWord=&srchTp=&multi_itm_seq=0&itm_seq_1=0&itm_seq_2=0&company_cd=&company_nm=&page=1&titleNm=. Updated October 13, 2020. Accessed August 16, 2021.

9. Kuitunen I, Artama M, Mäkelä L, Backman K, Heiskanen-Kosma T, Renko M. Effect of social distancing due to the COVID-19 pandemic on the incidence of viral respiratory tract infections in children in Finland during early 2020. *Pediatr Infect Dis J* 2020;39(12):e423-7.

10. Goldman RD, Grafeinstein E, Barclay N, Irvine MA, Portales-Casamar E. Paediatric patients seen in 18 emergency departments during the COVID-19 pandemic. *Emerg Med J* 2020;37(12):773-7.

11. Lin CF, Huang YH, Cheng CY, Wu KH, Tang KS, Chiu IM. Public health interventions for the COVID-19 pandemic reduce respiratory tract infection-related visits at pediatric emergency departments in Taiwan. *Front Public Health* 2020;8:604089.

12. Choi DH, Jung JY, Suh D, Choi JY, Lee SU, Choi YJ, et al. Impact of the COVID-19 outbreak on trends in emergency department utilization in children: a multicenter retrospective observational study in Seoul metropolitan area, Korea. *J Korean Med Sci* 2021;36(5):e44.

13. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD). https://www.who.int/standards/classifications/classification-of-diseases. Accessed June 2, 2021.

14. Hirata S, Nakamura Y, Yanagawa H. Incidence rate of recurrent Kawasaki disease and related risk factors: from the results of nationwide surveys of Kawasaki disease in Japan. *Acta Paediatr* 2001;90(1):40-4.

15. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. *J Clin Pharm Ther* 2002;27(4):299-309.

16. Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. *Eur J Pediatr* 2007;166(2):131-7.

17. Kleinman ME, Chameides L, Schexnayder SM, Samson RA, Hazinski MF, Atkins DL, et al. Part 14: pediatric advanced life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation* 2010;122(18 Suppl 3):S876-908.

18. Kang JM, Kim YE, Huh K, Hong I, Kim DW, Kim MY, et al. Reduction in Kawasaki Disease after nonpharmaceutical interventions in the COVID-19 era: a nationwide observational study in Korea. *Circulation* 2021;143(25):e2968-e2969.
19. Kim M, Chae KH, Chung YI, Hwang H, Lee M, Kim HK, et al. The effect of the look-back period for estimating incidence using administrative data. *BMC Health Serv Res* 2020;20(1):166.

20. Ristevski B, Chen M. Big data analytics in medicine and healthcare. *J Integr Bioinform* 2018;15(3):20170030.

21. Hara T, Furuno K, Yamamura K, Kishimoto J, Mizuno Y, Murata K, et al. Assessment of pediatric admissions for Kawasaki disease or infectious disease during the COVID-19 state of emergency in Japan. *JAMA Netw Open* 2021;4(4):e214475.

22. Iio K, Matsubara K, Miyakoshi C, Ota K, Yamaoka R, Eguchi I, et al. Incidence of Kawasaki disease before and during the COVID-19 pandemic: a retrospective cohort study in Japan. *BMJ Paediatr Open* 2021;5(1):e001034.

23. Ae R, Shibata Y, Kosami K, Nakamura Y, Hamada H. Kawasaki disease and pediatric infectious diseases during the coronavirus disease 2019 pandemic. *J Pediatr* 2021;239:50-58.e2.

24. Davis AL, Sunderji A, Marneni SR, Seiler M, Hall JE, Cotanda CP, et al. Caregiver-reported delay in presentation to pediatric emergency departments for fear of contracting COVID-19: a multi-national cross-sectional study. *CJEM* 2021;23(6):778-86.

25. Ciaccini B, Toniofi F, Marciano C, Faticato MG, Borali E, Pini Prato A, et al. Reluctance to seek pediatric care during the COVID-19 pandemic and the risks of delayed diagnosis. *Ital J Pediatr* 2020;46(1):87.

26. Lazzerini M, Barbi E, Apicella A, Marchetti F, Cardinale F, Trobia G. Delayed access or provision of care in Italy resulting from fear of COVID-19. *Lancet Child Adolesc Health* 2020;4(5):e10-1.

27. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet* 2020;395(10239):1771-8.

28. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. *N Engl J Med* 2020;383(4):334-46.

29. Ebina-Shibuya R, Namkoong H, Shibuya Y, Horita N. Multisystem inflammatory syndrome in children (MIS-C) with COVID-19: insights from simultaneous familial Kawasaki Disease cases. *Int J Infect Dis* 2020;97:373-3.

30. Fukuda S, Kaneta M, Miyake M, Ohya T, Miyakawa K, Iwamoto M, et al. A case of multisystem inflammatory syndrome in children in a Japanese boy: with discussion of cytokine profile. *Mod Rheumatol Case Rep* 2021;5(2):442-7.

31. Choe YJ, Choi EH, Choi JW, Eun BW, Eun LY, Kim YJ, et al. Surveillance of COVID-19-associated multisystem inflammatory syndrome in children, South Korea. *Emerg Infect Dis* 2021;27(4):1196-200.
37. Iio K, Uda K, Hataya H, Yasui F, Honda T, Sanada T, et al. Kawasaki disease or Kawasaki-like disease: influence of SARS-CoV-2 infections in Japan. *Acta Paediatr* 2021;110(2):600-4.

PUBMED | CROSSREF

38. Kim YJ, Park H, Choi YY, Kim YK, Yoon Y, Kim KR, et al. Defining association between COVID-19 and the multisystem inflammatory syndrome in children through the pandemic. *J Korean Med Sci* 2020;35(22):e204.

PUBMED | CROSSREF